Sushanta K Banerjee

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 13

Top Venues

Cells

PloS one

Molecular pharmaceutics

Journal of cell communication and signaling

Kansas City VA Medical Center

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Kansas City VA Medical Center Mar 26 1993

United States

Senior Research Scientist and Professor :: Cancer Reserarch Unit/Oncology

University of Kansas Medical Center

United States

Professor :: Pathology and Laboratory Medicne

Publications

Debasmita Dutta, Priyanka Ray, Archana De, Arnab Ghosh, Raj Shankar Hazra, Pratyusha Ghosh, Snigdha Banerjee, Francisco J Diaz, Sunil P Upadhyay, Mohiuddin Quadir, Sushanta K Banerjee
pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model. PloS one 19 (4) (2024)
Snigdha Banerjee, Affan A Ansari, Sunil P Upadhyay, Daniel J Mettman, Jamie R Hibdon, Mohiuddin Quadir, Pratyusha Ghosh, Anjali Kambhampati, Sushanta K Banerjee
Benefits and Pitfalls of a Glycosylation Inhibitor Tunicamycin in the Therapeutic Implication of Cancers. Cells 13 (5) (2024)
Snigdha Banerjee, Affan A Ansari, Sunil P Upadhyay, Daniel J Mettman, Jamie R Hibdon, Mohiuddin Quadir, Pratyusha Ghosh, Anjali Kambhampati, Sushanta K Banerjee
Benefits and Pitfalls of a Glycosylation Inhibitor Tunicamycin in the Therapeutic Implication of Cancers. Cells 13 (5) (2024)
Snigdha Banerjee, Affan A Ansari, Sunil P Upadhyay, Daniel J Mettman, Jamie R Hibdon, Mohiuddin Quadir, Pratyusha Ghosh, Anjali Kambhampati, Sushanta K Banerjee
Benefits and Pitfalls of a Glycosylation Inhibitor Tunicamycin in the Therapeutic Implication of Cancers. Cells 13 (5) (2024)
Snigdha Banerjee, Affan A Ansari, Sunil P Upadhyay, Daniel J Mettman, Jamie R Hibdon, Mohiuddin Quadir, Pratyusha Ghosh, Anjali Kambhampati, Sushanta K Banerjee
Benefits and Pitfalls of a Glycosylation Inhibitor Tunicamycin in the Therapeutic Implication of Cancers. Cells 13 (5) (2024)
Debasmita Dutta, Priyanka Ray, Archana De, Arnab Ghosh, Raj Shankar Hazra, Pratyusha Ghosh, Snigdha Banerjee, Francisco J Diaz, Sunil P Upadhyay, Mohiuddin Quadir, Sushanta K Banerjee
pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model. PloS one 19 (4) (2024)
Snigdha Banerjee, Affan A Ansari, Sunil P Upadhyay, Daniel J Mettman, Jamie R Hibdon, Mohiuddin Quadir, Pratyusha Ghosh, Anjali Kambhampati, Sushanta K Banerjee
Benefits and Pitfalls of a Glycosylation Inhibitor Tunicamycin in the Therapeutic Implication of Cancers. Cells 13 (5) (2024)
Debasmita Dutta, Priyanka Ray, Archana De, Arnab Ghosh, Raj Shankar Hazra, Pratyusha Ghosh, Snigdha Banerjee, Francisco J Diaz, Sunil P Upadhyay, Mohiuddin Quadir, Sushanta K Banerjee
pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model. PloS one 19 (4) (2024)
Lauren B Birkeness, Snigdha Banerjee, Mohiuddin Quadir, Sushanta K Banerjee
The role of CCNs in controlling cellular communication in the tumor microenvironment. Journal of cell communication and signaling (2022)
Amlan Das, Inamul Haque, Priyanka Ray, Arnab Ghosh, Debasmita Dutta, Mohiuddin Quadir, Archana De, Sumedha Gunewardena, Indranil Chatterjee, Snigdha Banerjee, Scott Weir, Sushanta K Banerjee
CCN5 activation by free or encapsulated EGCG is required to render triple-negative breast cancer cell viability and tumor progression. Pharmacology research & perspectives 9 (2) (2021)
Priyanka Ray, Debasmita Dutta, Inamul Haque, Gauthami Nair, Jiyan Mohammed, Meredith Parmer, Narendra Kale, Megan Orr, Pooja Jain, Snigdha Banerjee, Katie M Reindl, Sanku Mallik, Suman Kambhampati, Sushanta K Banerjee, Mohiuddin Quadir
pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer. Molecular pharmaceutics 18 (1) (2020)
Chowdhury S Abdullah, Priyanka Ray, Shafiul Alam, Narendra Kale, Richa Aishwarya, Mahboob Morshed, Debasmita Dutta, Cathleen Hudziak, Sushanta K Banerjee, Sanku Mallik, Snigdha Banerjee, Md Shenuarin Bhuiyan, Mohiuddin Quadir
Chemical Architecture of Block Copolymers Differentially Abrogate Cardiotoxicity and Maintain the Anticancer Efficacy of Doxorubicin. Molecular pharmaceutics 17 (12) (2020)
Arnab Ghosh, Sandipto Sarkar, Snigdha Banerjee, Fariba Behbod, Ossama Tawfik, Douglas McGregor, Stephanie Graff, Sushanta K Banerjee
MIND model for triple-negative breast cancer in syngeneic mice for quick and sequential progression analysis of lung metastasis. PloS one 13 (5) (2018)

Sushanta K Banerjee.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Sushanta K Banerjee